Literature DB >> 2128511

Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects.

P R Bieck1, E Nilsson, K H Antonin.   

Abstract

CGP 28014 A is a specific inhibitor of catechol-O-methyl transferase (COMT). The effect on COMT was assessed with the levodopa test in 5 unmedicated subjects and after pretreatment with 200-600 mg CGP 28014 p.o. Plasma concentrations of DOPA, 3-O-methyldopa (3OMD), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid were measured. CGP 28014 A decreased 3OMD not dose-related by 67% (p less than 0.05). This, and an increase of DOPAC shows COMT inhibition by this compound in humans.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2128511     DOI： 10.1007/978-3-7091-9113-2_53

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN： 0303-6995


  4 in total

Review 1.  Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

Authors:  S Kaakkola
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

2.  Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.

Authors:  E Nissinen; I B Lindén; E Schultz; P Pohto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

3.  Clinical pharmacology of the new COMT inhibitor CGP 28,014.

Authors:  P R Bieck; K H Antonin; G Farger; E B Nilsson; E K Schmidt; P Dostert; M Strolin Benedetti; P C Waldmeier
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996

4.  Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.

Authors:  M Törnwall; S Kaakkola; P Tuomainen; A Kask; P T Männistö
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.